☆ 4.5 Meeting Abstract

PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION

HEART (2013)

Journal

HEART

Volume 99, Issue -, Pages -

Publisher

BMJ PUBLISHING GROUP

DOI: 10.1136/heartjnl-2013-304019.265

Keywords

-

Categories

Cardiac & Cardiovascular Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Cell Biology

Platelet removal from human blood plasma improves detection of extracellular vesicle-associated miRNA

Jillian W. P. Bracht, Mandy Los, Monique A. J. van Eijndhoven, Britta Bettin, Edwin van der Pol, D. Michiel Pegtel, Rienk Nieuwland

Summary: This study investigated whether the analysis of EV-miRNA is affected by the presence of platelets and ery-ghosts in human plasma. The results showed that filtration of plasma can remove platelets and ery-ghosts, improving the comparability and reproducibility of EV-miRNA studies. The authors recommend measuring and reporting the plasma concentration of platelets for EV-miRNA studies, and filtering plasma before downstream analyses or storage in biobanks.

JOURNAL OF EXTRACELLULAR VESICLES (2023)

Add to Collection

Article Gastroenterology & Hepatology

MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases

Xiaolin Wang, Yong He, Bryan Mackowiak, Bin Gao

Summary: MicroRNAs are small, non-coding RNAs that play crucial roles in regulating liver functions and are associated with various liver diseases, making them promising for early diagnosis and treatment strategies. Continued research on miRNAs in the liver may lead to the identification of biomarkers and therapeutic targets for liver diseases in the future.

GUT (2021)

Add to Collection

Review Biochemistry & Molecular Biology

MicroRNAs as Potential Biomarkers in Gynecological Cancers

Joanna Miskiewicz, Aleksandra Mielczarek-Palacz, Joanna Magdalena Gola

Summary: MicroRNAs are non-coding transcripts that regulate the expression of genes involved in tumor development and control important cellular processes. They play a crucial role in the development of gynecological cancers and have the potential to be used as diagnostic biomarkers.

BIOMEDICINES (2023)

Add to Collection

Review Medicine, General & Internal

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Grzegorz Procyk, Dominika Klimczak-Tomaniak, Grazyna Sygitowicz, Mariusz Tomaniak

Summary: MicroRNAs play an important role in the regulation of gene expression in cardiovascular diseases (CVD), with miR-126 and miR-223 being of particular interest. Despite numerous studies, there is still no conclusive evidence on the clinical utility of miRNA expression levels. This review critically appraises the association between miRNA expression, cardiovascular risk, and on-treatment platelet reactivity, and provides insights on future developments in the field.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer

Luis Javier Martinez-Gonzalez, Victor Sanchez-Conde, Jose Maria Gonzalez-Cabezuelo, Alba Antunez-Rodriguez, Eduardo Andres-Leon, Inmaculada Robles-Fernandez, Jose Antonio Lorente, Fernando Vazquez-Alonso, Maria Jesus Alvarez-Cubero

Summary: miR-210-3p, miR-23c, miR-592, and miR-93-5p are suggested as potential biomarkers for risk stratification in prostate cancer, with miR-93-5p showing promise as a non-invasive biomarker. These miRNAs could be included in non-invasive strategies such as liquid biopsy for precision medicine in prostate cancer management.

BIOMEDICINES (2021)

Add to Collection

Article Oncology

A plasma miRNA-based classifier for small cell lung cancer diagnosis

Michela Saviana, Giulia Romano, Joseph McElroy, Giovanni Nigita, Rosario Distefano, Robin Toft, Federica Calore, Patricia Le, Daniel Del Valle Morales, Sarah Atmajoana, Stephen Deppen, Kai Wang, L. James Lee, Mario Acunzo, Patrick Nana-Sinkam

Summary: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Review Hematology

Methods to Investigate miRNA Function: Focus on Platelet Reactivity

Alix Garcia, Sylvie Dunoyer-Geindre, Richard J. Fish, Marguerite Neerman-Arbez, Jean-Luc Reny, Pierre Fontana

Summary: miRNAs, small noncoding RNAs regulating protein production, play crucial roles in cell function and are considered biomarkers in diseases. Development of techniques has led to models dedicated to miRNA study, and plasma samples are accessible for clinical trials. Extraction, purification techniques, and normalization procedures are important for comparing miRNA levels in populations and over time.

THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Cell Biology

Comprehensive Characterization of Platelet-Enriched MicroRNAs as Biomarkers of Platelet Activation

Teresa L. Krammer, Stephan Zeibig, Waltraud C. Schrottmaier, Anita Pirabe, Silvia Goebel, Andreas B. Diendorfer, Hans-Peter Holthoff, Alice Assinger, Matthias Hackl

Summary: This study provides comprehensive evidence that activated platelets release miRNAs, resulting in measurable changes in circulatory miRNA levels, making them promising biomarker candidates for platelet activation.

CELLS (2022)

Add to Collection

Article Multidisciplinary Sciences

A three-plasma miRNA panel predicts the risk of colorectal cancer: a community-based nested case-control study

Jia Liu, Binglin Chen, Man Yang, Yun Qian, Qian Shen, Hai Chen, Yunqiu Dong, Lu Wang, Jiandong Jiao

Summary: This study conducted a nested case-control study in a community-based population in China and identified three plasma miRNAs (miRNA-29a, miRNA-125b, miRNA-145) significantly associated with colorectal cancer risk, which may serve as potential biomarkers for early detection and individual risk prediction of colorectal cancer.

SCIENTIFIC REPORTS (2023)

Add to Collection

Review Medicine, General & Internal

Urinary Exosomal MicroRNAs as Biomarkers for Obesity-Associated Chronic Kidney Disease

Angel Earle, Madison Bessonny, Josh Benito, Kun Huang, Hannah Parker, Emily Tyler, Brittany Crawford, Nabeeha Khan, Bridget Armstrong, Alexis Stamatikos, Sudha Garimella, Alyssa Clay-Gilmour

Summary: The early detection of chronic kidney disease is crucial, and there is growing interest in finding new biomarkers. Currently, there is no single effective biomarker, but there is evidence supporting the use of urinary exosomal microRNAs as biomarkers for kidney fibrosis.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Endocrinology & Metabolism

Circulating MicroRNAs as Potential Diagnostic Biomarkers for Diabetic Retinopathy: A Meta-Analysis

Lingli Ma, Yan Wen, Zimeng Li, Nan Wu, Qing Wang

Summary: This study found that miRNAs can be used as potential diagnostic markers for DR, with high accuracy of diagnoses observed with the detection of miRNAs in plasma and serum.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma

Xiaohui Xu, Kritisha Bhandari, Chao Xu, Katherine Morris, Wei-Qun Ding

Summary: Pancreatic cancer is a major cause of cancer-related deaths, and early detection is crucial for improving survival rates. Recent studies suggest that miRNA signatures in plasma small EVs could be potential biomarkers for early detection of pancreatic cancer. However, inconsistent results have been reported due to the heterogeneity of plasma small EVs and isolation methods. In this study, a refined protocol for plasma small EV isolation was used, and miRNA signatures were analyzed in a pilot cohort of early-stage pancreatic cancer patients. The results showed that miR-18a and miR-106a levels were significantly elevated in the plasma small EVs of PDAC patients, indicating their potential as biomarkers for early detection.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Clinical Neurology

Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis

Jimin He, Yao Jiang, Liang Liu, Zhihua Zuo, Chun Zeng

Summary: A meta-analysis was conducted on 24 studies involving a total of 2,170 glioma patients and 1,456 healthy participants, which revealed the potential of circulating miRNAs as diagnostic biomarkers for gliomas, pending validation through large prospective studies.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Cell Biology

Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy

Claudia Sacchetto, Zenab Mohseni, Robin M. W. Colpaert, Libero Vitiello, Marzia De Bortoli, Indira G. C. Vonhogen, Ke Xiao, Giulia Poloni, Alessandra Lorenzon, Chiara Romualdi, Riccardo Bariani, Elisa Mazzotti, Luciano Daliento, Barbara Bauce, Domenico Corrado, Thomas Thum, Alessandra Rampazzo, Leon J. de Windt, Martina Calore

Summary: The study identified miR-185-5p as significantly upregulated in ARVC patients compared to healthy controls, with a confirmed link to ARVC pathophysiology based on receiver operating characteristic analysis.

CELLS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

Teresa L. L. Krammer, Marietta Kollars, Paul A. A. Kyrle, Matthias Hackl, Sabine Eichinger, Ludwig Traby

Summary: This study investigates the potential of plasma miRNAs as biomarkers for monitoring antiplatelet treatment. The results show that platelet-enriched miRNAs in the circulation are significantly reduced within 2 hours after P2Y12-mediated platelet inhibition, and higher baseline levels of these miRNAs are associated with a greater reduction upon antiplatelet therapy. Furthermore, the study suggests that miRNAs may be carried by platelet-derived and procoagulant extracellular vesicles.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Hematology

Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions

Sem A. O. F. Rikken, Robert F. Storey, Felicita Andreotti, Peter Clemmensen, Jurrien M. ten Berg

Summary: Oral inhibitors of the platelet P2Y(12) receptor play a crucial role in treating STEMI, but they have limitations in terms of delayed absorption and insufficient platelet inhibition during primary percutaneous coronary intervention. There is a clinical need for drugs that can provide rapid, effective, and safe platelet inhibition in the setting of STEMI. Novel parenteral antiplatelet drugs, such as cangrelor, selatogrel, and zalunfiban, have been developed to achieve rapid and potent antiplatelet effects while preserving hemostasis, offering a potential innovation in treatment options.

THROMBOSIS AND HAEMOSTASIS (2023)

Add to Collection

Article Medicine, General & Internal

Bariatric surgery prevents carotid wall thickness progression

Lukas Lunger, Andreas Melmer, Wolfgang Sturm, Claudia Lamina, Alexander Tschoner, Julia Engl, Armin Honlinger, Clemens Engler, Peter Willeit, Stefan Kiechl, Johann Willeit, Dietmar Ofner, Heinz Wykypiel, Markus Laimer, Herbert Tilg, Christoph Ebenbichler

Summary: The study demonstrates that weight loss induced by bariatric surgery can halt the natural progression of carotid intima media thickness (C-IMT) over a 10-year observation period, compared to a population-based control cohort.

WIENER KLINISCHE WOCHENSCHRIFT (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial

Marcus Hjort, Kai M. Eggers, Tatevik Ghukasyan Lakic, Johan Lindback, Andrzej Budaj, Jan H. Cornel, Evangelos Giannitsis, Hugo A. Katus, Agneta Siegbahn, Robert F. Storey, Richard C. Becker, Lars Wallentin, Bertil Lindahl

Summary: Investigating biomarker concentrations and their changes can provide new insights into the pathobiology of nonobstructive myocardial infarction (MINOCA). Patients with MINOCA have higher initial inflammatory activity, similar myocardial dysfunction, and faster recovery compared to those with MI with obstructive coronary artery disease.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Haemodynamic gain index is associated with risk of sudden cardiac death and improves risk prediction: a cohort study

Jari Laukkanen, Nzechukwu M. Isiozor, Peter Willeit, Setor K. Kunutsor

Summary: The study investigated the association between haemodynamic gain index (HGI) and sudden cardiac death (SCD) risk using data from a long-term prospective cohort study. The results showed that higher HGI levels were associated with a lower risk of SCD, with a dose-response relationship and dependence on cardiorespiratory fitness (CRF) levels. Addition of HGI to a SCD risk prediction model improved risk discrimination and reclassification, but CRF remained a stronger predictor of SCD.

CARDIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease

Pia Davidsson, Susanna Eketjall, Niclas Eriksson, Anna Walentinsson, Richard C. Becker, Anders Cavallin, Anna Bogstedt, Anna Collen, Claes Held, Stefan James, Agneta Siegbahn, Ralph Stewart, Robert S. Storey, Harvey White, Lars Wallentin

Summary: This study investigated the associations between circulating VEGF ligands and/or soluble receptors and cardiovascular (CV) outcomes in patients with acute coronary syndrome (ACS) and chronic coronary syndrome (CCS). The results showed that VEGF-D, KDR, Flt-1, and PlGF were significantly associated with CV outcomes. Furthermore, genetic variants of VEGFD were also found to be independently associated with CV outcomes.

CARDIOVASCULAR RESEARCH (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Davide Capodanno, Roxana Mehran, Mitchell W. Krucoff, Usman Baber, Deepak L. Bhatt, Piera Capranzano, Jean-Philippe Collet, Thomas Cuisset, Giuseppe De Luca, Leonardo De Luca, Andrew Farb, Francesco Franchi, C. Michael Gibson, Joo-Yong Hahn, Myeong-Ki Hong, Stefan James, Adnan Kastrati, Takeshi Kimura, Pedro A. Lemos, Renato D. Lopes, Adrian Magee, Ryosuke Matsumura, Shuichi Mochizuki, Michelle L. O'Donoghue, Naveen L. Pereira, Sunil V. Rao, Fabiana Rollini, Yuko Shirai, Dirk Sibbing, Peter C. Smits, P. Gabriel Steg, Robert F. Storey, Jurrien ten Berg, Marco Valgimigli, Pascal Vranckx, Hirotoshi Watanabe, Stephan Windecker, Patrick W. Serruys, Robert W. Yeh, Marie-Claude Morice, Dominick J. Angiolillo

Summary: Antiplatelet therapy is the main pharmacologic treatment for preventing thrombotic or ischemic events in patients with coronary artery disease, but it also increases the risk of bleeding complications. Defining the optimal intensity of platelet inhibition based on clinical presentation and individual patient factors is challenging. Modulating antiplatelet therapy involves adjusting the type, dose, or number of drugs to balance the risks of thrombotic events and bleeding. To address confusion in terminology, this study provides an overview and definitions of different strategies of antiplatelet therapy modulation for patients with coronary artery disease.

CIRCULATION (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding

Davide Cao, Nicolas Amabile, Mauro Chiarito, Victoria T. Lee, Dominick J. Angiolillo, Davide Capodanno, Deepak L. Bhatt, Michael J. Mack, Robert F. Storey, Michael Schmoeckel, C. Michael Gibson, Efthymios N. Deliargyris, Roxana Mehran

Summary: Significant progress has been made in the pharmacological management of cardiovascular disease, but bleeding complications remain common. Therapeutic interventions for antithrombotic drug reversal or removal have shown promising results but require careful consideration of the potential prothrombotic effects and risks associated with withdrawal of antithrombotic protection. There is a need for dedicated clinical investigations to understand the risk tradeoff in urgent high-risk settings, but challenges in trial design exist with practical, financial, and ethical implications.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Review Cell Biology

What can we learn from senescent platelets, their transcriptomes and proteomes?

Harriet E. Allan, Ami Vadgama, Paul C. Armstrong, Timothy D. Warner

Summary: Research on the natural aging process of platelets has attracted much attention in recent years. Previous studies have shown an association between the proportion of newly formed platelets in the circulation and the risk of thrombosis. However, these observations were mainly demonstrated in patient groups with underlying systemic changes. Recent technological advances have allowed in-depth analysis of differently aged platelets from healthy individuals, revealing extensive changes in the transcriptome and proteome of aged platelets. These changes result in deteriorated platelet function, impairing their ability to participate in hemostatic responses.

PLATELETS (2023)

Add to Collection

Review Obstetrics & Gynecology

Assessment of Cardiovascular Risk in Women: Progress so Far and Progress to Come

Lena Tschiderer, Lisa Seekircher, Peter Willeit, Sanne A. E. Peters

Summary: Cardiovascular disease is the leading cause of death in women worldwide, but there are uncertainties in prediction, diagnosis, and treatment. Risk scores are used for prediction, and pregnancy- and reproductive-factors may affect cardiovascular disease risk. However, adding female-specific factors to existing models does not significantly improve cardiovascular risk prediction. Further research is needed to determine if pregnancy-related factors improve risk prediction in young women for better prevention and treatment of cardiovascular disease.

INTERNATIONAL JOURNAL OF WOMENS HEALTH (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis

Bruna Gigante, Jerrold H. Levy, Eric van Gorp, Alessandro Bartoloni, Marie-Luce Bochaton-Piallat, Magnus Back, Hugo ten Cate, Christina Christersson, Jose Luis Ferreiro, Tobias Geisler, Esther Lutgens, Sam Schulman, Robert F. Storey, Jecko Thachil, Gemma Vilahur, Patricia C. Liaw, Bianca Rocca

Summary: Patients with severe infections and a pre-existing indication for antithrombotic therapy require integrated clinical counselling among coagulation, infectious disease, and cardiology specialists, due to sepsis-induced coagulopathy that frequently occurs. The association between bacterial and viral pathogens and patients with ongoing antithrombotic treatment is a growing threat to public health. This clinical consensus statement provides expert opinion and statements on the management of patients hospitalized for severe bacterial or viral infections with a pre-existing indication for antithrombotic therapy, in whom sepsis-induced coagulopathy is often observed.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

2023 ESC Guidelines for the management of acute coronary syndromes

Robert A. Byrne, Xavier Rossello, J. J. Coughlan, Emanuele Barbato, Colin Berry, Alaide Chieffo, Marc J. Claeys, Gheorghe-Andrei Dan, Marc R. Dweck, Mary Galbraith, Martine Gilard, Lynne Hinterbuchner, Ewa A. Jankowska, Peter Juni, Takeshi Kimura, Vijay Kunadian, Margret Leosdottir, Roberto Lorusso, Roberto F. E. Pedretti, Angelos G. Rigopoulos, Maria Rubini Gimenez, Holger Thiele, Pascal Vranckx, Sven Wassmann, Nanette Kass Wenger, Borja Ibanez, ESC Sci Document Grp

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction

Martine Gehin, Robert F. Storey, Corine Bernaud, Jasper Dingemanse

Summary: Selatogrel, a potent and reversible P2Y12 inhibitor administered subcutaneously, is under development for the treatment of acute myocardial infarction (AMI). Results from preclinical, phase 1, and phase 2 trials show that selatogrel provides rapid and pronounced P2Y12 receptor inhibition with a favorable safety profile.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

Juan Carlos Kaski, Nuria Lluch, Jose-Luis Lopez-Sendon, Diana A. Gorog, Isabel Antorrena-Miranda, Pablo Avanzas, Pablo Herrero Puente, Alessandro Sionis, Jose R. Gonzalez-Juanatey, Andres Iniguez, Alberto Cordero, Emmanuel Ako, Francisco Fernandez-Aviles, Felipe Atienza, Alejandro Recio-Mayoral, Alan H. B. Wu, Filippo Crea, Robert Storey, Lina Badimon, Judit Cubedo

Summary: This study suggests that circulating ApoJ-Glyc levels are associated with myocardial ischemia in patients with chest pain in the emergency department, even in the absence of troponin elevations. Therefore, ApoJ-Glyc may be a useful marker of myocardial ischemia in this setting.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Conservative versus Invasive Strategy in Elderly Patients with Non-ST-Elevation Myocardial Infarction: Insights from the International POPular Age Registry

Wout W. A. Van den Broek, Marieke E. Gimbel, Dean R. P. P. Chan Pin Yin, Jaouad Azzahhafi, Renicus S. Hermanides, Craig Runnett, Robert F. Storey, David Austin, Rohit Oemrawsingh, Justin Cooke, Gavin Galasko, Ronald J. Walhout, Dirk A. A. M. Schellings, Stijn L. Brinckman, Hong Kie The, Martin G. Stoel, Antonius A. C. M. Heestermans, Debby Nicastia, Mireille E. Emans, Arnoud W. J. Van 't Hof, Hannes Alber, Robert Gerber, Paul F. M. M. Van Bergen, Ismail Aksoy, Abdul Nasser, Paul Knaapen, Cees-Joost Botman, Anho Liem, Johannes C. Kelder, Jurrien M. ten Berg

Summary: This study assessed the impact of conservative and invasive strategies on major adverse clinical events in elderly patients with NSTEMI. It found that an early invasive strategy was associated with benefits over conservative management. Risk factors associated with ischemia and bleeding should guide strategy selection rather than solely relying on age.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study

M. P. Bonaca, E. Lesen, E. Giannitsis, J. Hedberg, T. Jernberg, D. Lambrelli, M. Duong, A. P. Maggioni, A. Ariza-Sole, J. ten Berg, R. F. Storey

Summary: This study provides insights into the real-world utilization of ticagrelor 60 mg in patients with prior myocardial infarction (MI) and its associated bleeding and ischemic outcomes. The observed event rates align with those in pivotal trials, reaffirming the safety profile of ticagrelor and highlighting the significant residual ischemic risk in this population.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.